V013-2193 Screening compound: 3,4-dichloro-N-{4-[4-(pyrrolidin-1-yl)piperidine-1-carbonyl]-1,3-thiazol-2-yl}benzamide

V013-2193 Screening compound: 3,4-dichloro-N-{4-[4-(pyrrolidin-1-yl)piperidine-1-carbonyl]-1,3-thiazol-2-yl}benzamide
V013-2193 Screening compound: 3,4-dichloro-N-{4-[4-(pyrrolidin-1-yl)piperidine-1-carbonyl]-1,3-thiazol-2-yl}benzamide alternative view

Chemical Structure Depiction of ChemDiv screening compound V013-2193
3,4-dichloro-N-{4-[4-(pyrrolidin-1-yl)piperidine-1-carbonyl]-1,3-thiazol-2-yl}benzamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

V013-2193

Molecular Formula

C20H22Cl2N4O2S (C20 H22 Cl2 N4 O2 S)

Compound Name

3,4-dichloro-N-{4-[4-(pyrrolidin-1-yl)piperidine-1-carbonyl]-1,3-thiazol-2-yl}benzamide

IUPAC name

34-dichloro-N-{4-[4-(pyrrolidin-1-yl)piperidine-1-carbonyl]-13-thiazol-2-yl}benzamide

SMILES

O=C(c1csc(NC(c(cc2)cc(Cl)c2Cl)=O)n1)N(CC1)CCC1N1CCCC1

InChI

InChI=1S/C20H22Cl2N4O2S/c21-15-4-3-13(11-16(15)22)18(27)24-20-23-17(12-29-20)19(28)26-9-5-14(6-10-26)25-7-1-2-8-25/h3-4,11-12,14H,1-2,5-10H2,(H,23,24,27)

InChI Key

JWXYLSPLUGBYGR-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD19976011

Chemical and Physical Properties

Saltdata

not_available

Molecular Weight

453.39

Hydrogen Bond Acceptors Count

6.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

6.00

Number of Nitrogen and Oxygen Atoms

6

Partition Coefficient, logP

4.300

Distribution Coefficient, logD

4.300

Water Solubility, LogSw

-4.57

Polar Surface Area

53.484

Acid Dissociation Constant (pKa)

6.45

Base Dissociation Constant (pKb)

11.28

Number of Chiral Centers

0.00

Percent sp3 carbon bonding

45.00

V013-2193 in Drug Discovery

Included in Screening Libraries

Allosteric Kinases Inhibitors Library (23117 compounds)

CNS Targets (44014 compounds)

Adenosine Receptors Targeted Library (19896 compounds)

Type II Kinase Inhibitors Library (6956 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Cancer
  • Female
  • Congenital
  • Skin
  • Nervous system
  • Cancer
  • Digestive system
  • Respiratory tract
  • Nervous system
  • Eye
  • Cardiovascular
  • Digestive system
  • Hemic and lymphatic
  • Endocrine
Targets:
  • Kinases
  • GPCR
  • Kinases
Mechanism of action:
  • Receptor's ligands

References: we are preparing a list of scientific research reports with V013-2193 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound V013-2193?
Check Price and Availability of V013-2193, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of V013-2193 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for V013-2193
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for V013-2193
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of V013-2193 available by request